Poppe Katrina K, Doughty Robert N
Department of Medicine, National Institute for Health Innovation, University of Auckland, Private Bag 92019, Auckland 1142, New Zealand.
Department of Medicine, National Institute for Health Innovation, University of Auckland, Private Bag 92019, Auckland 1142, New Zealand; Greenlane Cardiovascular Service, Auckland City Hospital, Private Bag 92024, Auckland 1142, New Zealand.
Heart Fail Clin. 2014 Jul;10(3):503-10. doi: 10.1016/j.hfc.2014.04.012.
Heart failure with preserved ejection fraction (HF-PEF) represents a heterogenous group of patients with HF, more commonly affecting older women, with a history of hypertension and, less commonly, coronary disease, than patients with HF with reduced ejection fraction (HF-REF). Patients with HF-PEF have lower short-term and longer-term mortality than patients with HF-REF. At present, therapeutic interventions that have had proven benefits for patients with HF with reduced EF have not been shown to have similar benefits for patients with HF-PEF and there remains an urgent need for new therapeutic strategies to improve the clinical outcomes for patients with HF-PEF.
射血分数保留的心力衰竭（HF-PEF）代表了一组异质性的心力衰竭患者，与射血分数降低的心力衰竭（HF-REF）患者相比，HF-PEF更常见于老年女性，有高血压病史，冠心病史则较少见。HF-PEF患者的短期和长期死亡率低于HF-REF患者。目前，已证实对射血分数降低的心力衰竭患者有益的治疗干预措施，对HF-PEF患者尚未显示出类似的益处，因此迫切需要新的治疗策略来改善HF-PEF患者的临床结局。
